Find clear guidance on Trulicity use in diabetes management, including ICD-10 codes for type 2 diabetes mellitus, clinical documentation improvement tips for GLP-1 receptor agonists, and healthcare provider resources for prescribing Trulicity. Learn about appropriate billing and coding for dulaglutide, dosage information, and best practices for incorporating Trulicity into diabetes treatment plans. This resource provides information for physicians, nurses, and medical coders seeking to optimize patient care and ensure accurate documentation and coding related to Trulicity.
Also known as
Type 2 diabetes mellitus
This code encompasses type 2 diabetes, the condition Trulicity is prescribed to manage.
Long term (current) drug therapy
Indicates ongoing medication use, including medications like Trulicity for diabetes.
Type 2 diabetes mellitus without complications
This code signifies type 2 diabetes without specified complications, where Trulicity may be used.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is Trulicity used for type 1 diabetes?
Yes
Code Z79.4 (Long term current drug therapy)
No
Is Trulicity used for type 2 diabetes?
When to use each related code
| Description |
|---|
| Trulicity Use in T2DM |
| Type 2 Diabetes Mellitus |
| Prediabetes |
Patient presents for ongoing management of type 2 diabetes mellitus. The patient's current regimen includes metformin and dietary modifications. HbA1c remains elevated at 8.2% despite adherence to the current treatment plan. The patient reports no significant hypoglycemic episodes. After discussing the risks and benefits of adding a glucagon-like peptide-1 receptor agonist (GLP-1 RA), the patient elected to initiate Trulicity (dulaglutide) injections. Treatment with Trulicity is indicated for improved glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. The patient understands the injection technique and potential side effects, including nausea, vomiting, and diarrhea. The patient was educated on the importance of continued blood glucose monitoring and regular follow-up appointments to assess treatment efficacy and adjust dosage as needed. Prescribed Trulicity 0.75mg subcutaneously once weekly. Diagnosis: Type 2 diabetes mellitus (ICD-10 E11.9). Plan: Continue metformin, initiate Trulicity, monitor HbA1c, and assess for side effects at the next appointment. Patient education provided regarding diabetes management, including medication adherence, healthy lifestyle choices, and regular self-monitoring of blood glucose.